The association of nutritional supplement TK3 to conventional treatment of cancer patients reduces the intensity and frequency of toxic effects and side effects caused by adjuvant or palliative treatments for the protection of healthy tissues, resulting in a better quality of life.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
80
Tritofano 160mg / Timina140mg and starch 150 mg
Placebo
Sana Casa de Avaré
Avaré, São Paulo, Brazil
RECRUITINGAssessment of Quality of Life
Using data from the toxicity of chemotherapy and tolerability of TK3 through the clinical course of patients with malignant CS III and IV with adjuvant or palliative chemotherapy or hormone therapy, associated or not to TK3.
Time frame: 0 day
Assessment of Quality of Life
Using data from the toxicity of chemotherapy and tolerability of TK3 through the clinical course of patients with malignant CS III and IV with adjuvant or palliative chemotherapy or hormone therapy, associated or not to TK3.
Time frame: 30 days
Assessment of Quality of Life
Using data from the toxicity of chemotherapy and tolerability of TK3 through the clinical course of patients with malignant CS III and IV with adjuvant or palliative chemotherapy or hormone therapy, associated or not to TK3.
Time frame: 60 days
Assessment of Quality of Life
Using data from the toxicity of chemotherapy and tolerability of TK3 through the clinical course of patients with malignant CS III and IV with adjuvant or palliative chemotherapy or hormone therapy, associated or not to TK3.
Time frame: 90 days
Assessment of Quality of Life
Using data from the toxicity of chemotherapy and tolerability of TK3 through the clinical course of patients with malignant CS III and IV with adjuvant or palliative chemotherapy or hormone therapy, associated or not to TK3.
Time frame: 120 days
Assessment of Quality of Life
Using data from the toxicity of chemotherapy and tolerability of TK3 through the clinical course of patients with malignant CS III and IV with adjuvant or palliative chemotherapy or hormone therapy, associated or not to TK3.
Time frame: 150 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Assessment of Quality of Life
Using data from the toxicity of chemotherapy and tolerability of TK3 through the clinical course of patients with malignant CS III and IV with adjuvant or palliative chemotherapy or hormone therapy, associated or not to TK3.
Time frame: 180 days
Performance status
Karnofsky index assesses the general condition of the patient according to the level of physical performance of the patient, which assesses the degree of functional impairment by questionnaire
Time frame: 0 day
Perfomance status
Karnofsky index assesses the general condition of the patient according to the level of physical performance of the patient, which assesses the degree of functional impairment by questionnaire
Time frame: 30 days
Performance Status
Karnofsky index assesses the general condition of the patient according to the level of physical performance of the patient, which assesses the degree of functional impairment by questionnaire
Time frame: 60 days
Performance Status
Karnofsky index assesses the general condition of the patient according to the level of physical performance of the patient, which assesses the degree of functional impairment by questionnaire
Time frame: 90 days
Performance Status
Karnofsky index assesses the general condition of the patient according to the level of physical performance of the patient, which assesses the degree of functional impairment by questionnaire
Time frame: 120 days
Performance Status
Karnofsky index assesses the general condition of the patient according to the level of physical performance of the patient, which assesses the degree of functional impairment by questionnaire
Time frame: 150 days
Performance Status
Karnofsky index assesses the general condition of the patient according to the level of physical performance of the patient, which assesses the degree of functional impairment by questionnaire
Time frame: 180 days
Tumor Markers
Analysis of tumor markers specific to each tumor
Time frame: 0 day
Tumor Markers
Analysis of tumor markers specific to each tumor
Time frame: 30 day
Tumor Markers
Analysis of tumor markers specific to each tumor
Time frame: 60 day
Tumor Markers
Analysis of tumor markers specific to each tumor
Time frame: 90 day
Tumor Markers
Analysis of tumor markers specific to each tumor
Time frame: 120 day
Tumor Markers
Analysis of tumor markers specific to each tumor
Time frame: 150 day
Tumor Markers
Analysis of tumor markers specific to each tumor
Time frame: 180 day